| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
- Japan
- LOI
- CA
- PEF
- Korea
- buyout
- securities
- Investment
- hong kong
- Letter of intent
- Bank
- Acquistion
- case study
- China
- nda
- capital gate
- taiwan
- LOTTE
- Malaysia
- acquisition
- Confidential Agreement
- cgi korea
- OTCBB
- Japan Tobacco
- M&A
- private equity
- China Construction Bank
- Merger
- sk
- Korea M&A
- Today
- Total
Korea M&A Corporation
Sinobiomed Inc. ("Sinobiomed", or "the Company") (OTCBB: SOBM) is pleased to update on the acquisition, by its 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. ("Shanghai Wanxing"), of Suzhou Boai Medical Development Co., Ltd. ("Suzhou Boai"). On August 26, 2007, the equity owners of Suzhou Boai holding 90% of the equity of Suzhou Boai formally transferred their equity owners..
SHANGHAI (XFN-ASIA) - China B-shares were sharply higher in early trade amid reports that the securities watchdog is still studying the reform of the B-share markets, dealers said. The Shanghai Securities News quoted Qi Bin, director-general of research and strategy at the CSRC, as saying it needs to proceed 'prudently' because market opinion on B-share reform is so diverse, with some proposals ..